View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
September 8, 2016

Deals this week: Cynata Therapeutics, Sun Pharmaceutical Industries, Cardinal Health

Cynata Therapeutics and Fujifilm Corporation have entered a term sheet for the development and commercialisation of a Cynata technology and its product CYP-001.

Cynata Therapeutics and Fujifilm Corporation have entered a term sheet for the development and commercialisation of a Cynata technology and its product CYP-001.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The partners will jointly finalise a definitive agreement by the fourth quarter of 2016, according to which, Fujifilm will invest up to $3m in Cynata by acquiring its shares, while Cyanta will provide Fujifilm an exclusive license to manufacture, market and sell its MSC products worldwide, along with certain rights to its technology.

The agreement also enables Cynata to receive certain upfront and milestone payments and royalty on end products.

Sun Pharmaceutical Industries (Sun Pharma) has entered a distribution agreement with Mitsubishi Tanabe Pharma Corporation to expand its sales in the Japanese pharmaceutical market, along with stable supply of medicines and healthcare information.

According to the agreement, Mitsubishi Tanabe Pharma will be responsible to market and distribute Sun Pharma’s 14 products and also provide their prescribing information to healthcare professionals.

The agreement enables Sun Pharma to expand its sales channel by transferring manufacturing and marketing rights of the 14 products.

Sanofi expects to raise gross proceeds of $1.28bn through a public offering of notes, due January 2027.

BNP Paribas SA and Morgan Stanley are acting as global co-ordinators and book runners for the offering, while Credit Agricole CIB S.A, Deutsche Bank AG, MUFG Americas Holdings Corporation and Natixis SA are acting as book runners.

The company plans to invest the funds for general corporate purposes.

Cardinal Health has announced that it has signed a letter of intent (LOI) with Navidea Biopharmaceuticals to acquire all rights to the latter’s Lymphoseek products of all FDA-approved, pending and future oncology diagnostic indications in North America.

"Sanofi expects to raise gross proceeds of $1.28bn through a public offering of notes, due January 2027."

According to the LoI, Cardinal Health will be responsible to make a total consideration of up to $310m for certain milestone and annual sales-based payments to Navidea Biopharmaceuticals.

Navidea will also receive a license to a portion of acquired intellectual property in order to develop, manufacture and market its new products and also license to market, manufacture and distribute Lymphoseek outside North America.

The agreement enables Cardinal Health to strengthen its product portfolio and will enable Navidea to repay its outstanding debts.

Sanofi has priced a public offering of its notes due in 2020 to raise $1.12bn. The company intends use the proceeds for general corporate purposes.


Image: BNP Paribas SA is acting as global co-ordinators and book runners for Sanofi's equity offering. Photo: courtesy of Tangopaso.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena